Painkillers
The first non-opioid painkiller
The non-opioid painkiller 'Journavx' (generic name: suzetrizine) developed by Vertex received FDA approval on January 30, 2025. While traditional opioids block pain sensations by acting on μ-receptors in the central nervous system, Journavx selectively blocks NaV1.8 ion channels found only in peripheral pain receptors, preventing pain signals from being transmitted to the brain.
Since it doesn't affect the brain, there's no risk of euphoria, respiratory depression, or addiction, and side effects are minimized. Currently approved only for acute pain, clinical trials for chronic pain indications (e.g., diabetic neuropathy) are ongoing. Priced at approximately $230 for a one-week supply, it's more expensive than mild opioids, making expanded insurance coverage a challenge.
